Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 9/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | STIM1 | Q13586 | 2/20 | 0.37 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | SNCA | P37840 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20636686 | 0.91 | BRD4 (0.41) | BRD4MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL23698896 | 0.84 | AMPD3 (0.41) | BRD4MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL23698834 | 0.83 | BRD4 (0.37) | BRD4MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL20636653 | 0.81 | CHRM1 (0.55) | — | |
| SCHEMBL20636651 | 0.81 | CHRM1 (0.55) | — | |
| SCHEMBL20636654 | 0.81 | CHRM1 (0.55) | — | |
| SCHEMBL17201244 | 0.81 | CD74 (0.41) | BRD4GSK3BDYRK1A | |
| SCHEMBL20636632 | 0.81 | CHRM1 (0.56) | — | |
| SCHEMBL19353594 | 0.81 | CHRM1 (0.56) | — | |
| SCHEMBL20636630 | 0.81 | CHRM1 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3428150-B1 | AROMATIC RING COMPOUND HAVING A CHOLINERGIC MUSCARINE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR ACTIVITY | TAKEDA PHARMACEUTICALS CO (JP) | 2023-07-12 | — | — | EP | disclosed |
| US-10548877-B2 | Aromatic ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-04 | — | — | US | disclosed |
| US-20190083467-A1 | AROMATIC RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-03-21 | — | — | US | disclosed |
| EP-3428150-A1 | AROMATIC RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190083467-A1 | AROMATIC RING COMPOUND | CHRM1, CHRM2, CHRM4 | BRD4 503/4885MEN1 1622/4885KMT2A 374/4885 |
| US-10548877-B2 | Aromatic ring compound | CHRM1, CHRM2, CHRM4 | BRD4 503/4885MEN1 1622/4885KMT2A 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.